BACKGROUND AND AIM: Medically managed opioid withdrawal (detox) can increase the risk of subsequent opioid overdose. We assessed the association between mortality following detox and receipt of medications for opioid use disorder (MOUD) and residential treatment after detox. DESIGN: Cohort study generated from individually linked public health data sets. SETTING: Massachusetts, USA. PARTICIPANTS: A total of 30 681 opioid detox patients with 61 819 detox episodes between 2012 and 2014. MEASUREMENTS: Treatment categories included no post-detox treatment, MOUD, residential treatment or both MOUD and residential treatment identified at monthly intervals. We classified treatment exposures in two ways: (a) 'on-treatment' included any month where a treatment was received and (b) 'with-discontinuation' individuals were considered exposed through the month following treatment discontinuation. We conducted multivariable Cox proportional hazards analyses and extended Kaplan-Meier estimator cumulative incidence for all-cause and opioid-related mortality for the treatment categories as monthly time-varying exposure variables. FINDINGS: Twelve months after detox, 41% received MOUD for a median of 3 months, 35% received residential treatment for a median of 2 months and 13% received both for a median of 5 months. In on-treatment analyses for all-cause mortality compared with no treatment, adjusted hazard ratios (AHR) were 0.34 [95% confidence interval (CI) = 0.27-0.43] for MOUD, 0.63 (95% CI = 0.47-0.84) for residential treatment and 0.11 (95% CI = 0.03-0.43) for both. In with-discontinuation analyses for all-cause mortality, compared with no treatment, AHRs were 0.52 (95% CI = 0.42-0.63) for MOUD, 0.76 (95% CI = 0.59-0.96) for residential treatment and 0.21 (95% CI = 0.08-0.55) for both. Results were similar for opioid-related overdose mortality. CONCLUSIONS: Among people who have undergone medically managed opioid withdrawal, receipt of medications for opioid use disorder, residential treatment or the combination of medications for opioid use disorder and residential treatment were associated with substantially reduced mortality compared with no treatment.
BACKGROUND AND AIM: Medically managed opioid withdrawal (detox) can increase the risk of subsequent opioid overdose. We assessed the association between mortality following detox and receipt of medications for opioid use disorder (MOUD) and residential treatment after detox. DESIGN: Cohort study generated from individually linked public health data sets. SETTING: Massachusetts, USA. PARTICIPANTS: A total of 30 681 opioid detox patients with 61 819 detox episodes between 2012 and 2014. MEASUREMENTS: Treatment categories included no post-detox treatment, MOUD, residential treatment or both MOUD and residential treatment identified at monthly intervals. We classified treatment exposures in two ways: (a) 'on-treatment' included any month where a treatment was received and (b) 'with-discontinuation' individuals were considered exposed through the month following treatment discontinuation. We conducted multivariable Cox proportional hazards analyses and extended Kaplan-Meier estimator cumulative incidence for all-cause and opioid-related mortality for the treatment categories as monthly time-varying exposure variables. FINDINGS: Twelve months after detox, 41% received MOUD for a median of 3 months, 35% received residential treatment for a median of 2 months and 13% received both for a median of 5 months. In on-treatment analyses for all-cause mortality compared with no treatment, adjusted hazard ratios (AHR) were 0.34 [95% confidence interval (CI) = 0.27-0.43] for MOUD, 0.63 (95% CI = 0.47-0.84) for residential treatment and 0.11 (95% CI = 0.03-0.43) for both. In with-discontinuation analyses for all-cause mortality, compared with no treatment, AHRs were 0.52 (95% CI = 0.42-0.63) for MOUD, 0.76 (95% CI = 0.59-0.96) for residential treatment and 0.21 (95% CI = 0.08-0.55) for both. Results were similar for opioid-related overdosemortality. CONCLUSIONS: Among people who have undergone medically managed opioid withdrawal, receipt of medications for opioid use disorder, residential treatment or the combination of medications for opioid use disorder and residential treatment were associated with substantially reduced mortality compared with no treatment.
Authors: Michael D Stein; Jessica N Flori; Megan M Risi; Micah T Conti; Bradley J Anderson; Genie L Bailey Journal: Subst Abus Date: 2017-07-10 Impact factor: 3.716
Authors: Alexander Y Walley; Debbie M Cheng; Emily K Quinn; Elena Blokhina; Natalia Gnatienko; Christine E Chaisson; Evgeny Krupitsky; Philip O Coffin; Jeffrey H Samet Journal: Int J Drug Policy Date: 2016-11-28
Authors: Travis P Baggett; Stephen W Hwang; James J O'Connell; Bianca C Porneala; Erin J Stringfellow; E John Orav; Daniel E Singer; Nancy A Rigotti Journal: JAMA Intern Med Date: 2013-02-11 Impact factor: 21.873
Authors: Alexandra Savinkina; Rajapaksha W M A Madushani; Golnaz Eftekhari Yazdi; Jianing Wang; Joshua A Barocas; Jake R Morgan; Sabrina A Assoumou; Alexander Y Walley; Benjamin P Linas; Sean M Murphy Journal: Addiction Date: 2022-04-12 Impact factor: 7.256
Authors: Benjamin P Linas; Alexandra Savinkina; R W M A Madushani; Jianing Wang; Golnaz Eftekhari Yazdi; Avik Chatterjee; Alexander Y Walley; Jake R Morgan; Rachel L Epstein; Sabrina A Assoumou; Sean M Murphy; Bruce R Schackman; Stavroula A Chrysanthopoulou; Laura F White; Joshua A Barocas Journal: JAMA Netw Open Date: 2021-02-01
Authors: Daniel M Hartung; Sheila Markwardt; Kirbee Johnston; Jonah Geddes; Robin Baker; Gillian Leichtling; Christi Hildebran; Brian Chan; Ryan R Cook; Dennis McCarty; Udi Ghitza; P Todd Korthuis Journal: Addict Sci Clin Pract Date: 2022-08-19
Authors: April M Young; Jennifer L Brown; Timothy Hunt; Linda S Sprague Martinez; Redonna Chandler; Emmanuel Oga; T John Winhusen; Trevor Baker; Tracy Battaglia; Rachel Bowers-Sword; Amy Button; Amanda Fallin-Bennett; Laura Fanucchi; Patricia Freeman; LaShawn M Glasgow; Jennifer Gulley; Charles Kendell; Michelle Lofwall; Michael S Lyons; Maria Quinn; Bruce David Rapkin; Hilary L Surratt; Sharon L Walsh Journal: BMJ Open Date: 2022-09-19 Impact factor: 3.006
Authors: Antoine Chaillon; Chrianna Bharat; Jack Stone; Nicola Jones; Louisa Degenhardt; Sarah Larney; Michael Farrell; Peter Vickerman; Matthew Hickman; Natasha K Martin; Annick Bórquez Journal: Addiction Date: 2021-12-04 Impact factor: 7.256
Authors: Jake R Morgan; Joshua A Barocas; Sean M Murphy; Rachel L Epstein; Michael D Stein; Bruce R Schackman; Alexander Y Walley; Benjamin P Linas Journal: JAMA Netw Open Date: 2020-12-01